# OnCo record splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli" ;
  schema:name "Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)"@en ;
  schema:alternateName "SBLPN"@en, "B-cell prolymphocytic leukaemia"@en, "B-cell prolymphocytic leukemia"@en, "B-PLL"@en, "Hairy cell leukaemia variant"@en, "HCL-v"@en, "Splenic B-cell lymphoma/leukemia with prominent nucleoli"@en ;
  schema:description "Splenic B-cell lymphoma/leukaemia with prominent nucleoli is the new WHO name for a rare group of B-cell leukaemias of older adults with a big spleen, large cells with obvious nucleoli and a poor response to standard treatment; it absorbs the old diagnoses B-cell prolymphocytic leukaemia and hairy cell leukaemia variant. It is treated with rituximab-based chemotherapy or newer targeted drugs."@en ;
  schema:url <https://onco.cc/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/B-cell_prolymphocytic_leukemia> ;
  schema:citation <https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1111/bjh.19754>, <https://doi.org/10.1182/blood.v89.6.2015>, <https://doi.org/10.4103/jcrt.jcrt_1931_22> ;
  onco:tag "subtype-page", "wave4", "haematologic", "rare" ;
  onco:related <https://onco.cc/cancers/leukaemia/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/hairy-cell-leukemia/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/t-cell-prolymphocytic-leukaemia/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:terms <https://onco.cc/terms/allogeneic-transplant/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/hairy-cell-leukemia/> .